Angina

Clinical Trial Finder

Many patients with angina are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

Effect of Amlodipine Versus Amlodipine Combined With Atorvastatin on the Coronary Vasospastic Angina

Condition:   Quality of Life
Interventions:   Drug: Caduet 10Mg-20Mg Tablet;   Drug: NorvasC® 10 mg Tablets
Sponsor:   Kosin University Gospel Hospital
Not yet recruiting - verified February 2017

The Impact of Depression and/or Anxiety on PCI Patients

Conditions:   Acute Coronary Syndrome;   MAjor Depressive Disorder;   Generalized Anxiety Disorder
Intervention:   Other: antidepressive and anti-anxiety therapy
Sponsors:   First Affiliated Hospital Xi'an Jiaotong University;   Shaanxi Provincial People's Hospital;   Xi'an Central Hospital;   Baoji Central Hospital;   Baoji People's Hospital;   General Hospital of Ningxia Medical University;   The People's Hospital of Ningxia;   Wuzhong People's Hospital;   The First Hospital of Lanzhou University;   LanZhou University;   First Affiliated Hospital of Xinjiang Medical University;   the People's Hospital of Xinjiang Uygur Autonomous Region;   The First People's Hospital of Kashgar Erea;   the First Division Hospital of Xinjiang Production and Construction Corps
Not yet recruiting - verified December 2016

Implication of Cardiac Shock Wave Therapy on Coronary Heart Disease

Condition:   Cardiac Ischemia
Interventions:   Device: Cardiac shock wave therapy;   Other: Sham cardiac shock wave (Control group)
Sponsor:   Beijing Hospital
Recruiting - verified February 2017

Adenovirus Vascular Endothelial Growth Factor D (AdvVEGF-D) Therapy for Treatment of Refractory Angina Pectoris

Conditions:   Refractory Angina Pectoris;   Gene Transfer;   Coronary Artery Disease
Interventions:   Drug: AdvVEGF-D;   Drug: Control Rx
Sponsors:   Kuopio University Hospital;   Queen Mary University of London;   University College, London;   Medizinische Universitaet Wien;   Servicio Madrileño de Salud, Madrid, Spain;   FinVector Vision Therapies Oy;   Śląski Uniwersytet Medyczny w Katowicach;   Rigshospitalet, Denmark;   Euram Limited
Not yet recruiting - verified January 2017

Comparing TR Band to Statseal in Conjunction With TR Band

Conditions:   Arterial Occlusion;   Angina Pectoris;   Cardiovascular Diseases;   Atherosclerosis;   Hematoma;   Anticoagulant-Induced Bleeding;   Coronary Artery Disease
Interventions:   Device: StatSeal;   Device: TR Band
Sponsor:   VA Long Beach Healthcare System
Not yet recruiting - verified February 2017

Use of Different Diagnostic Coronary Catheters Over the Radial Access - the UDDC - Radial Trial

Condition:   Stable Coronary Heart Disease
Interventions:   Device: One-catheter concept;   Device: Standard catheter
Sponsor:   Charite University, Berlin, Germany
Completed - verified February 2017

Comprehensive Treatment of Angina in Women With Microvascular Dysfunction

Conditions:   Angina Pectoris;   Coronary Microvascular Disease
Interventions:   Dietary Supplement: Diet;   Behavioral: Training;   Drug: Medication (with statin and ACE-inhibition)
Sponsors:   Bispebjerg Hospital;   University Hospital Bispebjerg and Frederiksberg;   Cambridge Weight Plan Limited
Recruiting - verified February 2017

Open-Label Study of Perhexiline in Patients With Hypertrophic Cardiomyopathy and Moderate to Severe Heart Failure

Conditions:   Cardiomyopathy, Hypertrophic;   Cardiomyopathy, Hypertrophic, Familial
Intervention:   Drug: Perhexiline
Sponsor:   Heart Metabolics Limited
Recruiting - verified February 2017

In the Management of Coronary Artery Disease, Does Routine Pressure Wire Assessment - at the Time of Coronary Angiography - Affect Management Strategy, Hospital Costs and Outcomes?

Conditions:   Chest Pain;   Stable Angina;   Acute Coronary Syndrome;   Non ST Segment Elevation Acute Coronary Syndrome
Intervention:   Device: Routine Measurement of FFR
Sponsors:   University Hospital Southampton NHS Foundation Trust;   Liverpool Heart and Chest Hospital NHS Foundation Trust
Recruiting - verified February 2017

Role of Podocan and Wnt Pathway Regulatory Molecules in Coronary Artery Disease

Condition:   Coronary Artery Disease
Intervention:  
Sponsors:   Bassett Healthcare;   Baylor University
Recruiting - verified February 2017

Clinical Study of Medicinal Product Cardionat® Using in Health Athlete Volunteers

Conditions:   Stroke, Not Specified as Hemorrhage or Infarction;   Angina Pectoris
Intervention:   Drug: оral intake of study drug capsules; study drug - Cardionat ® (trimethylhydrazinium propionate dihydrate), oral capsules 250 mg
Sponsor:   Burnasyan Federal Medical Biophysical Center
Active, not recruiting - verified February 2017

COMBO-Stent in Patients on Chronic Anticoagulant Therapy (COSTA) COSTA-Bleed and COSTA-Outcome Trials

Conditions:   Stable Angina;   Unstable Angina;   STEMI;   NSTEMI;   Coronary Disease
Interventions:   Device: COMBO-Stent;   Drug: Clopidogrel, Vitamin K Antagonist, Rivaroxaban, Dabigatran;   Device: Any drug eluting stent oder bare metal sent;   Drug: ASA, Clopidogrel, Vitamin K Antagonist, Rivaroxaban, Dabigatran
Sponsors:   IHF GmbH - Institut für Herzinfarktforschung;   OrbusNeich
Withdrawn - verified February 2017

A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: semaglutide;   Drug: placebo
Sponsor:   Novo Nordisk A/S
Recruiting - verified February 2017

Treadmill CV Safety Study

Condition:   Stable Angina
Interventions:   Drug: AMG 334;   Drug: Placebo
Sponsor:   Amgen
Active, not recruiting - verified February 2017

Effect of ACE-Inhibition on Microvascular Function in Women With Assessed Microvascular Dysfunction

Condition:   Microvascular Angina
Interventions:   Drug: Ramipril (ACE-inhibitor);   Drug: placebo
Sponsor:   Bispebjerg Hospital
Completed - verified February 2017

Impact of Enhanced External Counterpulsation (EECP) on VO2 MAX

Conditions:   Cardiovascular Disease;   Pulmonary Disease
Intervention:   Device: Enhanced External Counterpulsation (EECP)
Sponsor:   David Grant U.S. Air Force Medical Center
Recruiting - verified February 2017

Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus
Interventions:   Biological: Albiglutide 30 mg;   Biological: Albiglutide 50 mg;   Biological: Albiglutide matching placebo
Sponsors:   GlaxoSmithKline;   Duke Clinical Research Institute
Active, not recruiting - verified February 2017

Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease, on Dialysis

Condition:   Anemia
Interventions:   Drug: Roxadustat;   Drug: Epoetin alfa
Sponsors:   AstraZeneca;   FibroGen
Recruiting - verified February 2017

Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease (CKD), Not on Dialysis

Condition:   Anemia
Interventions:   Drug: Roxadustat;   Drug: Placebo
Sponsors:   AstraZeneca;   FibroGen
Recruiting - verified February 2017

Objective Randomised Blinded Investigation With Optimal Medical Therapy of Angioplasty in Stable Angina

Condition:   Stable Angina
Intervention:   Procedure: Coronary angioplasty
Sponsors:   Imperial College London;   Volcano Corporation
Recruiting - verified February 2017

The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects

Condition:   Cardiovascular Disease
Interventions:   Drug: bococizumab (PF-04950615);   Drug: Placebo
Sponsor:   Pfizer
Terminated - verified February 2017

The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects

Condition:   Cardiovascular Disease
Interventions:   Drug: bococizumab (PF-04950615);   Drug: Placebo
Sponsor:   Pfizer
Terminated - verified February 2017

Sirolimus-eluting Stents With Biodegradable Polymer Versus an Everolimus-eluting Stents

Conditions:   Coronary Artery Disease;   Angina Pectoris;   Myocardial Infarction
Interventions:   Device: Sirolimus-eluting stent with a bioresorbable polymer (Orsiro);   Device: Everolimus-eluting stent with a durable polymer
Sponsors:   University Hospital Inselspital, Berne;   Biotronik AG;   University of Bern
Active, not recruiting - verified February 2017

A Study to Assess the Efficacy and Safety of Enteric-Coated Acetylsalicylic Acid in Patients at Moderate Risk of Cardiovascular Disease

Condition:   Moderate Risk of CVD
Interventions:   Drug: Aspirin (Acetylsalicylic acid, BAYE4465);   Drug: Placebo
Sponsor:   Bayer
Completed - verified February 2017

Exercise-training Before Coronary Artery Bypass Graft (CABG)

Conditions:   Angina;   Coronary Artery Disease
Intervention:   Behavioral: Exercise training
Sponsor:   Norwegian University of Science and Technology
Completed - verified February 2017